Compare Abbott Laboratories (ABT) vs Crowdstrike Holdings Inc (CRWD) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abbott Laboratories vs Crowdstrike Holdings Inc — how do they compare? Abbott Laboratories trades at $95.55 (market cap $166.94B), while Crowdstrike Holdings Inc trades at $188.84 (market cap $198.17B). The key difference: Crowdstrike Holdings Inc is the larger of the two by market cap, and Abbott Laboratories pays a 2.63% dividend while Crowdstrike Holdings Inc pays none. Which is the better fit depends on your goals.
| ABT | CRWD | |
|---|---|---|
Market Cap | $166.94B | $198.17B |
Sector | Health | Technology |
52-Week High | $136.62 | $199.38 |
52-Week Low | $82.57 | $87.56 |
Enterprise Value | $193.69B | $194.44B |
Dividend Yield | 2.63% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $95.63, up 0.25% on the day, with a bullish technical signal from moving averages and strong analyst support. The stock shows solid fundamentals with a P/E of 26.79 and net income margin of 13.91%, though recent earnings have been mixed. Recent news highlights regulatory approvals for new medical devices, supporting growth prospects.
The outlook remains positive with a consensus price target of $122.55, implying significant upside. Key risks include competitive pressures and macroeconomic headwinds, but strong institutional backing and consistent dividend payments provide stability for long-term investors.
CrowdStrike (CRWD) trades at $194.62, up 0.43% today, with a strong technical outlook showing bullish momentum and key resistance at $199. The stock recently completed a 4-for-1 split, enhancing accessibility. Revenue growth accelerated to 26% year-over-year in Q1 2026, with EPS consistently beating estimates, though net margins remain negative. Analyst sentiment is overwhelmingly positive with 76% buy ratings and a $180.33 consensus target, despite premium valuations like a P/E of 765.
Outlook remains optimistic due to robust cybersecurity demand and AI-driven threats, but high valuation and profitability challenges pose risks. Investors should weigh growth potential against elevated multiples and competitive pressures in the sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About Crowdstrike Holdings Inc
CrowdStrike Holdings provides cybersecurity products and services aimed at protecting organizations from cyberthreats. It offers cloud-delivered protection across endpoints, cloud workloads, identity and data, and threat intelligence, managed security services, IT operations management, threat hunting, identity protection, and log management. CrowdStrike went public in 2019 and serves customers worldwide.
Read more on CRWD →
